×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Tag: NAN

Broker News

NAN – Morgans rates the stock as Upgrade to Add from Hold

July 24, 2020 - by Broker News

Even though the August profit release may cause some price weakness, Morgans prefers to get in early with a upgrade to Add, given the share price is -10% below the broker’s target price of $6.92. The post-result weakness may arise from limited hospital access in the last few months.

Read More
Broker News

NAN – Morgans rates the stock as Downgrade to Hold from Add

May 20, 2020 - by Broker News

Share price of Nanosonics has been relatively stable during this period of pandemic-generated volatility, observes Morgans.

Read More
Shares / Video

Where Are The Opportunities In Australian Small-Caps?

April 30, 2020April 30, 2020 - by Tim McGowen

Sam Twidale, Portfolio Manager for the DNR Capital Australian Emerging Companies Fund, explains why he believes recent volatility in equity markets has provided some excellent opportunities in the smaller cap sector.

Read More
Shares

Three Businesses To Weather The Storm

March 16, 2020March 16, 2020 - by Andrew Page

Andrew Page of Strawman.com highlights three Australian companies with net cash and zero debt that should offer safe harbour at this time.

Read More
Shares / Video

Nanosonics Post Reporting Season Update

September 10, 2019October 10, 2019 - by Tim McGowen

DNR Capital Portfolio Manager Sam Twidale last discussed Nanosonics (ASX:NAN) back in April 2019. Since that time the share price has rallied strongly from the mid $4 level back in April to touching $7 since reporting in late August.The DNR Capital Australian Emerging Companies Fund currently holds a 6% position in Nanosonics.

Read More
Broker News

NAN – Morgans rates the stock as Downgrade to Hold from Add

June 19, 2019 - by Broker News

The share price has rallied over 30% in the last month and Morgans downgrades to Hold from Add. Second half operating earnings (EBITDA) are forecast to be less than the first half so, potentially, some weakness is likely to follow when the company reports in late August.

Read More
Shares / Video

trophon How The Technology Works

April 17, 2019July 25, 2019 - by Company

trophon’s high-frequency ultrasonic vibrations generate a sonically activated, supercharged hydrogen peroxide (H2O2) mist that kills bacteria, fungi and viruses.

Read More
Shares / Video

How trophon2 Works

April 16, 2019July 25, 2019 - by Company

Tap into trophon2 the latest innovation in automated ultrasound probe high-level disinfection. Easy to Set up, Simple to Use that delivers fast and efficient workflows… so you have more time to focus on your patients.

Read More
Shares / Video

DNR Capital: Talking Stock – Nanosonics (ASX:NAN)

April 15, 2019July 25, 2019 - by Tim McGowen

DNR Capital’s Sam Twidale shares some insights with Informed Investor about Sydney-based medical technology company Nanosonics (ASX: NAN).

Read More
Broker News

NAN – Morgans rates the stock as Add

November 10, 2017May 14, 2019 - by Broker News

The broker has remodeled its assumptions for Nanosonics with regard management equipment service agreements and also added in contributions form new products.

Read More
Broker News

NAN – Morgans rates the stock as Add

February 1, 2016May 14, 2019 - by Broker News

December quarter sales were up 41% on the prior quarter, as North American direct sales gained momentum. Morgans adjusts its revenue growth assumptions to 40% from 25% to reflect the stronger installed base in the US.

Read More
James Dunn

Nanosonics Set to Clean Up Globally

November 26, 2014May 14, 2019 - by James Dunn

Medical device maker Nanosonics (NAN) may be a small Australian company, but it has high-powered support in rolling out its innovative disinfection technology.

Read More
Richard Campbell

Nanosonics Revenue Lift Encourages Baillieu Holst

April 8, 2014May 14, 2019 - by Richard Campbell

Small-cap broker interest in Nanosonics is relatively broad, but Baillieu has jumped ahead of the pack with a TP of $1.15, a 30-35% lift on current trade.

Read More
  • Inauguration Inflation
  • Lunch Report: Aussie market bounces back
  • Optimistic Investing Belies an Uncertain Outlook
  • The Unknown Unknowns
  • Australia…One Hour In…ASX up 67 points
  • ELD – Citi rates the stock as Buy
  • SUL – Credit Suisse rates the stock as Outperform
  • CGF – Morgans rates the stock as Hold

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Heart.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Truck.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Star.